Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer (NAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01090128
Recruitment Status : Terminated (Drug Manufacturer withdrew support for studies not in metastatic breast cancer)
First Posted : March 19, 2010
Last Update Posted : March 31, 2017
Celgene Corporation
Information provided by (Responsible Party):
University of Utah

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : March 24, 2017
  Actual Study Completion Date : March 24, 2017